InflaRx (IFRX)
Develops C5a-pathway medicines centered on oral izicopan for inflammatory and renal diseases.
Something off on this page? Send us feedback.
Develops C5a and C5aR inhibitors for inflammatory diseases. Its oral lead program, izicopan, is being advanced for ANCA-associated vasculitis and renal diseases, while vilobelimab remains available in the United States under an emergency authorization for specified COVID-19 patients.
Develops inhibitors of the complement pathway C5a and C5aR for inflammatory diseases. The programs apply selective complement-pathway intervention. Izicopan, an oral C5aR inhibitor, is the lead development program, with planning underway for ANCA-associated vasculitis and evaluation in additional renal diseases.
Vilobelimab is an intravenous anti-C5a antibody available in the United States under an emergency authorization for defined hospitalized adults with COVID-19; it is not FDA-approved for that use. The Jena-based group also has operations in Germany and Ann Arbor, while resource allocation predominantly favors izicopan and further hidradenitis suppurativa work depends on a partner.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 14, 2026 | Needham | Initiate | Rating: — | |
| May 13, 2026 | Raymond James | Upgrade | Target: $2 | Target: $9 |
| Dec 3, 2025 | Leerink Partners | Downgrade | Target: — | Target: $2 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $180.4M · Total debt $948.4K · Total assets $190.0M · Shareholders' equity $166.4M
- Revenue
- $0
- Operating income
- −$8.0M
- Net income
- −$12.1M
Reported in EUR, converted at the latest exchange rate
No dividends on record.
| Institutions | 65.32% | 94.45M ADS | |
|---|---|---|---|
| 67 holders · as of Jun 30, 2026 | |||
| Insiders | 6.01% | 8.69M ADS | |
| 7 holders · as of Mar 18, 2026 | |||
| Strategic holders | 24.21% | 35.00M ADS | |
| 2 holders · as of May 12, 2026 | |||
| Other | 4.46% | 6.45M ADS | |
| remainder | |||
144.59M ADS (1 ADS = 1 ordinary shares) as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
TCG Crossover GP III, LLCStrategic | 20.06% | 29.00M | filed May 12, 2026 |
Suvretta Capital Management, LLCInstitution | 15.86% | 22.93M ADS | as of Jun 30, 2026 |
Sirenia Capital Management LPInstitution | 12.33% | 17.82M | filed Aug 14, 2026 |
TCG Crossover Management, LLCInstitution | 10.03% | 14.50M ADS | as of Jun 30, 2026 |
FMR LLCInstitution | 5.65% | 8.16M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Amgen
Marketed oral C5aR therapy in ANCA-associated vasculitis
- Novartis (ADR)
Oral complement inhibitor across IgAN and C3 glomerulopathy
- Biogen
Owner of approved C3 therapy for C3 glomerulopathy
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| InflaRx | $2.02 | −3.13% | $306.4M | — | — | — | — |
| Amgen | $407.12 | −0.76% | $221.41B | 25.5 | 17.4 | 5.8 | +9.7% |
| Novartis (ADR) | $142.63 | +0.95% | $268.53B | 21.3 | 15.2 | 4.8 | +0.9% |
| Biogen | $223.12 | −1.00% | $33.30B | 39.9 | 16.8 | 3.3 | +3.4% |
| Median | 25.5 | 16.8 | 4.8 | +3.4% |